Ramosetron on Late PONV (Postoperative Nausea and Vomiting)

• Status: Completed
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the effectiveness of additional ramosetron injection for controlling late postoperative nausea and vomiting (PONV) after breast surgery in high risk PONV patients. The investigators compared PONV amomng 3 groups- group C: no additional ramosteron, group B: two additional ramosteron doses at 12 hour interval, group M: two additional ramosetron doses mix to the intraveonus patient controlled analgesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pusan National University Hospital
• Treatments: Ramosetron

Criteria

Inclusion Criteria:

• age over 18 years, American Society of Anesthesiologists (ASA) physical status I or II, requesting IV PCA (patient control of analgesia) for pain control, and the high-risk group of PONV with a score of 3 or more as measured by the Apfel's score.

Exclusion Criteria:

• emergency operation, re-operation, drug abuse, allergy, major organ disease (gastrointestinal, cardiovascular, respiratory, cerebral, renal or hepatic disease), smoker, pregnancy, lactation, previously use of antiemetics or systemic steroids within 48 before surgery